Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy

Melanoma Research

Volumn 11, Issue 4, 2001, Pages 423-431

  Roberts, M S ^a   Wu, Z Y ^a   Siebert, G A ^a   Anissimov, Y G ^a   Thompson, J F ^b   Smithers, B M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Isolated limb infusion; Kaposi's sarcoma; Melanoma; Melphalan; Merkel cell tumour; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; INTERMETHOD COMPARISON; LIMB PERFUSION; MALE; MELANOMA; METASTASIS; MORBIDITY; PERMEABILITY; PRIORITY JOURNAL; TREATMENT PLANNING;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, MERKEL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSION PUMPS; LEG; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; SARCOMA, KAPOSI; SKIN NEOPLASMS; TIME FACTORS;

EID: 0034898169     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200108000-00014     Document Type: Article

References (29)

1. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb
2. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit
3. Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion
4. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion
5. Pharmacokinetics of melphalan in isolated perfusion of the limbs
6. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities
7. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion
8. Pharmacokinetics of melphalan during isolated limb infusion for melanoma
9. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb
10. Pharmacokinetics of melphalan in isolated limb perfusion
11. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions
12. High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions
13. Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma
14. Availability predictions by hepatic elimination models for Michaelis-Menten kinetics
15. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination
16. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations
17. Mechanism of melphalan resistance developed in vitro in human melanoma cells
18. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines
19. Implications of kinetic heterogeneity in clinical oncology
20. Assessment of regional perfusion for melanoma by peroperative transcutaneous oxygen tension measurement
21. Comparison of the permeability surface product (ps) of the blood capillary wall in skeletal muscle tissue of various species and in vitro porous membranes using hydrophilic drugs
22. 51Cr]EDTA in human forearm
23. Capillary permeability measured by bolus injection, residue and venous detection
24. 131I-albumin in the resting human forearm
25. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: Application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb
26. Hydrolysis and protein binding of melphalan
27. A comparison of melphalan levels achieved in isolated limb perfusion and systemic high dose therapy
28. Hyperthermic isolated perfusion in the treatment of melanoma: Technical aspects
29. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma